Lytix Biopharma AS (OL:LYTIX) — Market Cap & Net Worth
Market Cap & Net Worth: Lytix Biopharma AS (LYTIX)
Lytix Biopharma AS (OL:LYTIX) has a market capitalization of $73.64 Million (Nkr699.79 Million) as of July 22, 2026. Listed on the OL stock exchange, this Norway-based company holds position #20354 globally and #179 in its home market, demonstrating a -5.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lytix Biopharma AS's stock price Nkr9.10 by its total outstanding shares 76900005 (76.90 Million). See Lytix Biopharma AS (LYTIX) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Lytix Biopharma AS Market Cap History: 2021 to 2026
Lytix Biopharma AS's market capitalization history from 2021 to 2026. Data shows change from $111.27 Million to $73.64 Million (-13.08% CAGR).
Lytix Biopharma AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lytix Biopharma AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.27x
Lytix Biopharma AS's market cap is 4.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $111.27 Million | $17.00K | -$48.05 Million | 6545.08x | N/A |
| 2022 | $62.79 Million | $1.41 Million | -$56.01 Million | 44.57x | N/A |
| 2023 | $39.33 Million | $3.99 Million | -$87.90 Million | 9.85x | N/A |
| 2024 | $47.58 Million | $11.13 Million | -$94.27 Million | 4.27x | N/A |
Competitor Companies of LYTIX by Market Capitalization
Companies near Lytix Biopharma AS in the global market cap rankings as of July 22, 2026.
Key companies related to Lytix Biopharma AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #560 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $480.50 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $672.15 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €753.60 |
| #560 | UCB SA | BR:UCB | $47.34 Billion | €238.00 |
Lytix Biopharma AS Historical Marketcap From 2021 to 2026
Between 2021 and today, Lytix Biopharma AS's market cap moved from $111.27 Million to $ 73.64 Million, with a yearly change of -13.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr73.64 Million | -7.89% |
| 2025 | Nkr79.95 Million | +68.03% |
| 2024 | Nkr47.58 Million | +20.99% |
| 2023 | Nkr39.33 Million | -37.37% |
| 2022 | Nkr62.79 Million | -43.56% |
| 2021 | Nkr111.27 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of Lytix Biopharma AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $73.64 Million USD |
| MoneyControl | $73.64 Million USD |
| MarketWatch | $73.64 Million USD |
| marketcap.company | $73.64 Million USD |
| Reuters | $73.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lytix Biopharma AS
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more